A 67-year-old male who started hydrochlorothiazide 12.5 mg 7 weeks ago now presents with foamy urine and back pain; what assessment and treatment should be undertaken?

Assessment and Management of Foamy Urine and Back Pain in a Patient Recently Started on Hydrochlorothiazide

Immediate Assessment Priority

Stop hydrochlorothiazide immediately and evaluate for acute kidney injury, electrolyte disturbances, and nephrolithiasis. Foamy urine appearing 7 weeks after starting HCTZ suggests either significant proteinuria from glomerular injury or nephrolithiasis-related complications, both of which require urgent evaluation and discontinuation of the offending agent 1.

Diagnostic Workup

Urinalysis and Urine Studies

• Obtain urinalysis with microscopy to assess for proteinuria (foamy urine), hematuria, red cell casts, acanthocytes, and crystalluria 2
• Quantify proteinuria with spot urine protein-to-creatinine ratio (PCR); significant proteinuria (>200 mg/g or >20 mg/mmol) indicates glomerular disease requiring further investigation 2
• Examine urine sediment for erythrocyte morphology and presence of red cell casts, which would suggest glomerular disease rather than nephrolithiasis 2
• 24-hour urine collection for calcium, oxalate, citrate, and uric acid if nephrolithiasis is suspected 3

Blood Work

• Serum creatinine and BUN to assess for acute kidney injury; HCTZ can cause renal dysfunction, particularly in elderly patients 1
• Serum electrolytes (sodium, potassium, chloride) to detect hyponatremia, hypokalemia, or hypochloremia—all common HCTZ complications 1
• Serum calcium and uric acid to evaluate for hypercalcemia or hyperuricemia, which can occur with thiazide therapy 1, 4

Imaging

• Non-contrast CT of abdomen/pelvis (CT KUB) if nephrolithiasis is suspected based on back pain location and urinalysis findings; this is the gold standard for detecting kidney stones 3
• Renal ultrasound as an alternative if CT is contraindicated, though less sensitive for small stones 3

Common Pitfalls and Key Considerations

Thiazide-Induced Complications in Elderly Patients

• Elderly patients (>65 years) are at significantly higher risk for HCTZ adverse effects, including hyponatremia, hypokalemia, and renal dysfunction 1
• Severe hyponatremia (Na <125 mEq/L) can present with nonspecific symptoms like weakness and requires immediate HCTZ discontinuation 5
• Hypokalemia is the most common adverse effect and can be severe, particularly when combined with other medications 1

Nephrolithiasis Paradox

• While thiazides are used to prevent calcium stone recurrence by reducing urinary calcium excretion, they can paradoxically cause acute stone formation through volume depletion and hypercalciuria in the initial weeks of therapy 3, 4
• HCTZ 12.5 mg daily is subtherapeutic for stone prevention; effective doses are 50 mg daily or 25 mg twice daily, but this patient's dose suggests hypertension treatment, not stone prevention 6, 7, 8

Glomerular Disease Considerations

• Do not start or continue ACE inhibitors/ARBs if the patient presents with abrupt-onset nephrotic syndrome (significant proteinuria with edema), as these can cause acute kidney injury, especially in minimal change disease 2
• Foamy urine with significant proteinuria warrants nephrology referral for possible kidney biopsy if PCR >200 mg/g and no alternative explanation is found 2

Treatment Algorithm

If Nephrolithiasis is Confirmed

1. Discontinue HCTZ permanently 3
2. Provide analgesia with acetaminophen or opioids; avoid NSAIDs as they worsen renal function and can cause diuretic resistance 9, 10
3. Increase fluid intake to achieve urine output >2 L/day for stone passage 3
4. Urology referral if stone >5 mm, persistent obstruction, or refractory pain 3
5. For future stone prevention, if needed, use chlorthalidone 25-50 mg daily or indapamide 2.5 mg daily instead of HCTZ, as these are more effective 10, 7

If Glomerular Disease is Suspected

1. Discontinue HCTZ immediately 2
2. Urgent nephrology referral for proteinuria >200 mg/g with consideration for kidney biopsy 2
3. Start ACE inhibitor or ARB only after excluding minimal change disease and ensuring stable renal function; target maximally tolerated dose 2
4. Monitor renal function closely; up to 30% increase in creatinine is acceptable when starting RAS blockade, but stop if function continues to worsen 2

If Acute Kidney Injury from Volume Depletion

1. Stop HCTZ 1
2. Assess volume status clinically; if hypovolemic, provide intravenous normal saline 9
3. Correct electrolyte abnormalities aggressively, particularly hypokalemia (target K ≥4.0 mEq/L) and hyponatremia 9
4. Recheck renal function and electrolytes within 1-3 days after stopping HCTZ 9

Alternative Antihypertensive Strategy

If HCTZ was prescribed for hypertension, switch to an alternative first-line agent:

• ACE inhibitor or ARB if proteinuria is present (once glomerular disease is excluded) 2, 11
• Calcium channel blocker (amlodipine) if no proteinuria 11
• Chlorthalidone 12.5 mg daily if a thiazide is still preferred, as it is more effective than HCTZ and has better cardiovascular outcomes, though it carries similar risks 10, 11

Monitoring After HCTZ Discontinuation

• Recheck electrolytes and renal function 1-3 days after stopping HCTZ, then weekly until stable 9
• Repeat urinalysis in 2-4 weeks to ensure resolution of proteinuria or hematuria 2
• Blood pressure monitoring to ensure adequate control with alternative therapy 11